Introduction
Bacterial meningitis is a serious lifethreatening disease with severe neurological emergency such as hearing loss, developmental disorders, and neuropsychological impairment, occurring in up to 50% of survivors of the disease. 1 The clinical signs of bacterial meningitis include fever, headache, meningismus, an altered level of con sciousness, and so on. 2 It is ranked fourth as a cause of disability, and the estimated incidence is 1-2 million cases per year worldwide. 3 Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis are the leading causes, still resulting in unacceptably high levels of human mortality and morbidity. 4 Although routine vac cination against the common pathogens has decreased the burden of disease, improved the outcomes, and had a notable effect on the prevalence of bacterial meningitis, 5, 6 correspondence: Xiujie Wu Department of neurosurgery, linyi People's hospital, 27 Jiefang road, linyi 276000, People's republic of china Tel +86 539 812 9102 Fax +86 539 812 9909 email xiujiewuxjw@163.com 
1244
shao et al due to global emergence of multidrugresistant bacteria, an estimated 1.2 million cases occur worldwide every year and 180,000 deaths in children aged 1-59 months were reported in 2010. 7, 8 In addition, bacterial meningitis often causes hear ing loss and is fatal in 5%-40% of children and 20%-50% of adults despite treatment with adequate antibiotics. 9 Early diagnosis and rapid initiation of empiric antimicrobial and adjunctive therapy are vital. Therefore, therapy should be initiated as soon as blood cultures have been obtained, pre ceding any imaging studies.
Corticosteroids, which have metabolic and regulatory functions in humans, are a class of steroid hormones that are produced in the adrenal cortex of vertebrates and the synthetic analogs of these hormones. They are implicated in a wide range of physiological processes such as stress response, immune response, inflammation regulation, carbohydrate metabolism, and protein catabolism. 10 Corticosteroids can also attenuate the intrathecal inflammatory response caused by infection and are used as an adjunct to antibiotics in the treatment of bacterial meningitis, reducing the mortality and morbidity. 11 Dexamethasone is a type of corticosteroid medication. 12, 13 The use of dexamethasone was significantly associated with improved cancerrelated fatigue and quality of life.
14 Dexamethasone therapy has been implemented as adjunctive treatment for bacterial meningitis and is cor related with a lower mortality and fewer neurological and auditory sequelae in adults and children. 15 Moreover, the adjunctive dexamethasone therapy can improve survival for years in the acute phase in adults with communityacquired bacterial meningitis. 16 Although several studies have shown that dexametha sone was used as a complementary therapy to antibac terials, it is still not clear whether it is effective in the treatment of bacterial meningitis because of the disparate findings from clinical trials and clinical evidence, 17 and empirical use of dexamethasone in bacterial meningitis appears controversial. 18, 19 Borchorst and Møller 20 found that dexamethasone treatment might be correlated with lower mortality and fewer neurological and auditory sequelae in adults and children from highincome coun tries, especially in adults suffering from pneumococcal meningitis. However, Peterković et al 21 did not substantiate the reported benefits of adjunctive dexamethasone in adult bacterial meningitis based on 20 years of experience in daily practice. Therefore, we conducted this metaanalysis to systematically evaluate the role of dexamethasone in bacterial meningitis.
Materials and methods literature search
The electronic databases of PubMed, Embase, Medline, and the Chinese biomedicine literature were used to retrieve rel evant articles published between January 2000 and 2016. The MeSH terms were "bacterial meningitis", "dexamethasone or corticosteroids", "treatment or therapy", and their combina tions. We also manually searched the references of retrieved articles to obtain more resources. We considered only those studies that were written in English and Chinese.
inclusion criteria
The eligible articles must meet the following criteria: 1) randomized, doubleblind, placebocontrolled trials of dexamethasone in the treatment of bacterial meningitis; 2) the diagnosis of bacterial meningitis was accepted in the presence of positive cerebrospinal fluid (CSF) culture, positive blood culture, positive latex agglutination test, or suggestive CSF cytology and biochemical profile; 22 3) the primary outcomes were death at the time of first followup, severe neurological sequelae at first followup, and severe bilateral hearing loss at first followup; and 4) the search was focused on studies that had been conducted in humans.
Data extraction
Two of our authors independently assessed the quality of the included studies based on the descriptions provided by the authors of the included trials. Any disagreement was subse quently resolved by discussion with a third author to reach a final consensus on each item. The following information was extracted from each included article: the name of first author, year of publication, country, study period, age range, sample size, diagnostic criteria, dexamethasone dose, and primary outcomes.
statistical analyses
Statistical analyses were conducted in Review Manager (Version 5.2, The Cochrane Collaboration). The overall effect was measured by odds ratios (ORs) and risk ratios (RRs) with their 95% confidence interval (CI). The sig nificance of the pooled ratios was determined by the Ztest with a Pvalue ,0.05 considered statistically significant. The I 2 test and the Qstatistic test were employed to cal culate the betweenstudy heterogeneity. The fixedeffect model was used when the Pvalue for the Qtest was .0.10 and I 2 for the I 2 test was ,50%; otherwise, the random effect model was used when the effect was heterogeneous. 
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The evidence of publication bias was assessed by visual funnel plot inspection. The sensitivity analysis was used to assess whether our results were substantially influenced by the presence of any individual study.
Results

characteristics of included studies
After applying the inclusion criteria, a total of ten articles were finally screened out, including 2,459 patients (1,245 in the dexamethasone group and 1,214 in the placebo group) with bacterial meningitis. Figure 1 presents the process of literature search. The ten articles (two were written in Chinese 23, 24 and eight in English [25] [26] [27] [28] [29] [30] [31] [32] ) were conducted in six countries (the Netherlands, India, Malawi, Vietnam, Brazil, and the People's Republic of China). All the patients were confirmed by clinically suspected bacterial meningitis plus CSF or blood criteria. The characteristics of the studies included in this analysis are listed in Table 1 .
curative effect analysis of dexamethasone in the treatment of bacterial meningitis
Follow-up mortality
All the ten articles reported the followup mortality of dexamethasone in the treatment of bacterial meningitis. No significant betweenstudy heterogeneity was observed, and the fixedeffect model was used. Overall, we found that the frequency of followup mortality in the dexamethasone group was a little lower than that in the placebo group (23.5% versus 25.9%), but the statistical analysis proved that dexametha sone was not associated with a significant reduction in death (OR =0.91, 95% CI =0.80-1.03, P=0.14) as shown in Figure 2 . Subgroup analysis by age group showed that dexamethasone was not correlated with followup mortality reduction either in adults (OR =0.93, 95% CI =0.79-1.09, P=0.39) or in children (OR =0.88, 95% CI =0.71-1.08, P=0.22).
hearing loss
Nine articles reported the incidence of hearing loss. Our result found that the frequency of hearing loss in the dexa methasone group was lower than that in the placebo group (21.2% versus 26.1%), and the statistical analysis found that dexamethasone was associated with a significant reduction in hearing loss (OR =0.76, 95% CI =0.59-0.98, P=0.03) as shown in Figure 3 .
neurological sequelae
Eight articles considered the role of dexamethasone in severe neurological sequelae of patients with bacterial meningitis. Our result demonstrated that dexamethasone was not associ ated with a significant reduction in severe neurological seque lae (22.4% versus 24.1%, OR =0.84, 95% CI =0.54-1.29, P=0.42) in the randomeffect model as shown in Figure 4 . 
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Adverse effect
Adverse events included gastrointestinal bleeding, hyperglyce mia, hydrocephalus, blindness, second fever, and so on. These adverse events showed no significant difference between the dexamethasone group and the placebo group (P.0.05).
sensitivity analysis and publication bias
We conducted a sensitivity analysis by systematically remov ing each study and recalculating the significance of the result to confirm whether each study influenced the overall results. Our result found that the pooled RRs and ORs were not significantly changed. The funnel plots were used to evaluate the publication bias. All the plots were found to be roughly symmetrical, indicating no publication bias as shown in Figure 5 .
Discussion
In this metaanalysis, we totally screened out ten articles, including 2,459 patients. Our result found that dexamethasone was not associated with a significant reduction in followup mortality (P=0.14) and severe neurological sequelae (P=0.42). However, dexamethasone seemed to reduce hear ing loss among survivors (P=0.03). No significant difference was found between these two groups in adverse events. Our results were consistent with those of previous metaanalysis, which showed that adjunctive dexamethasone in the treatment of acute bacterial meningitis did not seem to significantly reduce death or neurological disability but reduced the hear ing loss among survivors. 33 Bacterial meningitis is a severe acute infectious disease. The intense inflammatory host's response is potentially fatal and contributes to the neurological sequelae. The poor outcomes are mainly due to secondary systemic and intracranial complications resulting from a consequence of the inflammatory response to the invading pathogen and release of bacterial components by the pathogen itself. 34 The inflammatory reaction involving the meninges, the subarach noid space, and the brain parenchymal vessels was shown to contribute to neuronal injury. 35 The harmful inflammatory response is initiated by the recognition of bacterial products through pattern recognition receptors. 36 Despite effective antimicrobial therapy, the morbidity and mortality still remain high. Adequate and prompt treatment of bacterial meningitis is critical to outcome.
Dexamethasone is used to treat many inflammatory and autoimmune conditions. It can trigger a wide cellular response modulating the expression of genes involved in the innate immune system, growth, and stress and increases sus ceptibility to bacterial disease. 37 Highdose dexamethasone was shown to modulate serum cytokine profile in patients with primary immune thrombocytopenia. 38 Dexamethasone is often administered before antibiotics in cases of bacterial 
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shao et al meningitis. It then acts to reduce the inflammatory response of the body to the bacteria killed by the antibiotics (bacterial death releases proinflammatory mediators that can cause a response that is harmful to the patient), thus improving prognosis and outcome. 39 Many studies have identified the role of dexamethasone in the treatment of bacterial meningitis. However, the results still remain inconclusive. Bodilsen et al 40 proved that patients treated with dexamethasone were more likely to have a favorable outcome. BaunbaekKnudsen et al 41 indicated that adjuvant corticosteroid treatment in acute bacterial meningi tis improved the outcome and could safely be administered in an elderly population with high levels of immunosuppressive comorbidity. Heckenberg et al 42 suggested that adjunctive dexa methasone was widely prescribed for patients with meningococcal meningitis, was not associated with harm, and the rate of arthritis had decreased after the implementation of dexa methasone. Weisfelt et al 43 showed that treatment with adjunctive dexamethasone was not associated with an increased risk for longterm cognitive impairment. Brouwer et al 44 demonstrated that the corticosteroid dexamethasone did not significantly reduce the death rate, but patients treated with corticosteroids had significantly lower rates of severe hearing loss, any hearing loss, and neurological sequelae.
The combination of dexamethasone plus other antibodies might be the new treatment strategy for patients with bacte rial meningitis. Kasanmoentalib et al 45 found that adjunc tive treatment with dexamethasone plus antiC5 antibodies improved the survival in severe experimental meningitis caused by S. pneumoniae serotype 3. Vivas et al 46 showed that lowdose daptomycin was affected by concomitant use of dexamethasone, suggesting that the combination appeared to be a good choice for the treatment of pneumococcal meningitis. Du et al 47 suggested that dexamethasone could downregulate the expression of AQP4 in the brain tissue of rats with meningitis and provided evidence for the mecha nism of protective effect of dexamethasone on the central nervous system. Dexamethasone may also have some adverse effect in the treatment of bacterial meningitis. Leib et al 48 demonstrated that dexamethasone as adjuvant therapy increased hippocam pal cell injury and reduced learning capacity in the model of pneumococcal meningitis in infant rats. Spreer et al 49 found that dexamethasone increased the rate of apoptotic neurons in the granular layer of the hippocampal dentate gyrus in rabbits with Escherichia coli meningitis.
There were several limitations in our present metaanalysis. First, the event numbers of each included study were too small to show whether results were positive or negative. Second, dex amethasone in the treatment of bacterial meningitis was all short course therapy, thus less side effects were reported. Third, the performance of adjunctive therapy with dexa methasone in bacte rial meningitis was shown to be dependent on circumstances; 50 therefore, other related factors should be considered. Finally, the dexamethasone dose and empiric antibiotic therapy were differ ent in each study, which may have influenced our results.
Conclusion
Our results indicated that patients with bacterial meningitis neither benefit from nor are harmed by treatment with adjunc tive dexamethasone. Future welldesigned, largesample studies are still needed to further evaluate the role of dexa methasone in the treatment of bacterial meningitis.
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